BOSTON, March 14, 2025 /PRNewswire/ — SmartSKN, a leader in K-Beauty technology, announces the launch of K-OWN. This AI-driven platform empowers consumers to create their own custom Korean skincare tailored to their individual needs.
Redefining Custom Skincare
K-OWN is powered by SmartSKN’s proprietary AI technology, allowing users to build their own skincare formulations based on their unique skin concerns. The platform is integrated with SmartSKN’s robotic mini-labs, which produce freshly made, custom skincare in minutes. This ensures each product is designed for maximum efficacy while minimizing waste.
How It Works
Consumers can access the K-OWN platform through SmartSKN.com and engage in a seamless, step-by-step customization process:
This on-demand approach eliminates overproduction and excess inventory, making K-OWN a more sustainable alternative to mass-produced skincare.
Clinically Proven Skincare with Visible Results
K-OWN formulations are backed by clinical studies demonstrating immediate and measurable improvements in key skin concerns.
In clinical trials, 100% of participants reported:
A Simplified Yet Powerful Routine
The K-OWN product line offers a streamlined three-step skincare system that delivers maximum results with minimal effort:
Skin Empowerment Through Innovation
K-OWN is more than just a skincare line. It’s a revolution in customized beauty. By merging AI-driven precision with robotic manufacturing, SmartSKN Labs is setting a new standard for custom skincare that is efficient, effective, and sustainable.
Val Neicu, CEO and Co-Founder of SmartSKN, states:
“K-OWN puts the power of product creation into the hands of the consumer. It’s the beginning of a new era of customization in beauty, and it is all possible thanks to AI advancements.”
To learn more about K-OWN and experience the future of custom Korean skincare, visit www.smartskn.com.
For media inquiries, contact pr@smartskn.com.
SOURCE SmartSKN, LLC
New multilingual capabilities expand access to real-time GLP-1 dining guidance as WHO highlights the importance…
ATLANTA, GA AND DOHA, QATAR / ACCESS Newswire / December 6, 2025 / Ameerex Corporation…
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…